Adult Primary Hepatocellular Carcinoma (HCC)

Adult primary hepatocellular carcinoma (HCC) is a cancer that starts in the main cells of the liver called hepatocytes. It is “primary” because it begins in the liver, not spread from somewhere else. Most adults who develop HCC already have liver damage from chronic hepatitis B or C, long-term alcohol use, fatty liver disease, or chemical toxins such as aflatoxin. Over years, ongoing injury makes scar tissue (cirrhosis). Cirrhosis changes the liver environment and helps abnormal cells grow into a tumor. HCC can be a single lump, several nodules, or a diffuse growth. It may invade blood vessels in the liver and can spread to nearby organs or distant sites. Doctors stage HCC using imaging, liver function, and a person’s daily activity level. Treatment choices depend on tumor size and number, blood vessel involvement, spread, and liver reserve. Curative options include resection (surgery), ablation, or transplant in early stages. When cure is not possible, systemic drug therapy, radiation, and interventional procedures can slow disease and improve survival. Modern first-line systemic therapy commonly uses immunotherapy plus anti-angiogenic therapy or dual-immunotherapy, based on strong trial evidence and major guidelines. PMCNew England Journal of MedicinePubMedNCCN

Adult primary hepatocellular carcinoma (HCC) is a cancer that starts inside the liver, in the main liver cells called hepatocytes. It is the most common type of primary liver cancer in adults. Most people who get HCC already have long-term liver damage such as cirrhosis, but some people—especially those with chronic hepatitis B—can develop HCC even without cirrhosis. HCC can be found early by regular checks in people at risk. Doctors can often diagnose HCC based on special imaging patterns on CT or MRI, without a biopsy, when the patterns are typical. Early detection improves the chance of cure. Cancer.gov+1PMC

Other names

Hepatocellular carcinoma is also called HCC. Some people still say hepatoma, but many experts avoid this word because it sounds like a benign (non-cancer) tumor and can cause confusion. You may also see primary liver cancer used when the cancer starts in the liver itself (not spread from somewhere else). NCBICancer Research UK

Types

Doctors describe HCC in a few simple ways:

By growth pattern in the liver. A single large mass, many nodules, or an infiltrative (spread-out) pattern. These patterns are seen on scans and help planning. PMC

By imaging category (LI-RADS). On contrast CT or MRI, HCC often shows bright enhancement in the arterial phase and then looks less bright (washout) later, sometimes with a capsule. Lesions with these features in at-risk livers are called LI-RADS 5 (definite HCC). PMCAASLDRadiopaedia

By microscopic variant (pathology). Common (“conventional”) HCC and less common variants such as fibrolamellar, steatohepatitic, clear cell, scirrhous, and macrotrabecular-massive. These variants can behave a bit differently. PMC

---

Causes and strong risk factors

1. Chronic hepatitis B (HBV). HBV can cause HCC with or without cirrhosis because the virus can integrate into human DNA. Vaccination lowers risk but survivors of infection remain at risk. World Health OrganizationPMCGut

2. Chronic hepatitis C (HCV). HCV leads to scarring and cirrhosis over time; HCC risk stays even after cure if cirrhosis remains. hepatitisc.uw.edu

3. Cirrhosis from any cause. Scarring of the liver is the strongest common pathway to HCC. PMC

4. Aflatoxin exposure. A natural toxin from mold on foods (for example, poorly stored maize or groundnuts) that raises HCC risk, especially with HBV. IARC PublicationsCancer.gov

5. Alcohol-related liver disease. Heavy drinking causes cirrhosis and increases HCC risk. American Cancer Society

6. Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and NASH. Fatty liver with inflammation raises risk, especially with diabetes. PMC

7. Type 2 diabetes. Independently adds risk and often coexists with MASLD. PMC

8. Obesity. Raises risk through fatty liver pathways. American Cancer Society

9. Smoking. Adds extra HCC risk in many studies. American Cancer Society

10. Hereditary hemochromatosis. Iron overload damages the liver and increases HCC risk. American Cancer Society

11. Alpha-1 antitrypsin deficiency. Rare genetic condition that can progress to cirrhosis and HCC. American Cancer Society

12. Wilson disease (copper overload). Can cause cirrhosis and raise HCC risk. American Cancer Society

13. Autoimmune hepatitis. Long-term inflammation causes cirrhosis and HCC risk. PMC

14. Primary biliary cholangitis and other chronic cholestatic diseases. Cirrhosis from these diseases raises risk. PMC

15. Chronic hepatitis D (HDV) in people with HBV. Makes liver damage worse and speeds cancer risk. PMC

16. Synergy of HBV plus aflatoxin. The combination multiplies HCC risk compared with either alone. IARC Publications

17. Male sex and older age. Not causes by themselves, but risk is higher in adult men and with increasing age. PMC

18. Anabolic-androgenic steroid exposure. Linked to liver tumors including HCC in long-term use. PMC

19. Budd–Chiari syndrome and chronic venous outflow blockage. Long-term injury and nodules can lead to HCC. PMC

20. Family history of HCC or certain genetic changes (e.g., TERT pathway). Raises personal risk on top of liver disease. PMC

(Professional guidelines emphasize HBV, HCV, cirrhosis, alcohol, and MASLD/NASH as the leading global drivers today.) PMCJournal of Hepatology

---

Symptoms and signs

1. No symptoms at first. Many people feel well until tumors grow or the liver decompensates. Cleveland Clinic

2. Tiredness and weakness. Common in chronic liver disease and cancer.

3. Loss of appetite and weight loss. The body uses energy fighting the tumor.

4. Upper right-side abdominal pain or fullness. The enlarging liver capsule gets stretched.

5. Feeling a mass under the right ribs. The liver can feel big and firm.

6. Nausea or early fullness after small meals. The enlarged liver presses on the stomach.

7. Jaundice (yellow eyes/skin). Tumor or liver failure reduces bile flow.

8. Itching. Due to bile salts in the skin when bile does not drain well.

9. Abdominal swelling (ascites). Fluid collects because of portal hypertension and low albumin.

10. Leg swelling. Low albumin and portal pressure cause edema.

11. Fever or general unwell feeling. Tumor-related inflammation.

12. Dark urine and pale stools. Bile flow is blocked.

13. Easy bruising or bleeding. The sick liver makes fewer clotting proteins.

14. Confusion or sleep-wake reversal (hepatic encephalopathy). Toxins build up when the liver fails.

15. Bone pain or cough if cancer spreads to bone or lung (advanced disease). Cleveland Clinic

Diagnostic tests

A) Physical examination

1. Look for jaundice and muscle wasting. Yellow eyes/skin and weight loss suggest advanced liver disease or blocked bile.

2. Feel the liver for size and texture. A hard, bumpy edge under the right ribs can point to HCC on top of cirrhosis.

3. Check for ascites. A swollen belly suggests portal hypertension or cancer-related fluid.

4. Look for “stigmata” of chronic liver disease. Spider veins on the skin, red palms, and breast tissue in men are common in cirrhosis.

(These bedside findings guide urgency, but do not confirm HCC on their own.) PMC

B) Manual/bedside tests

5. Shifting dullness (percussion for fluid). Helps confirm free fluid in the belly when the patient turns side to side.

6. Fluid wave test. A tap on one side of the abdomen sends a wave you can feel on the other, suggesting ascites.

7. Scratch test for liver size. Light scratching while listening with a stethoscope helps outline the lower liver edge when it is hard to feel.

8. Asterixis (“flapping tremor”). Hands held out start to flap if the brain is affected by liver failure.

(These bedside maneuvers assess the background liver disease that often coexists with HCC.) PMC

C) Laboratory and pathology tests

9. Liver function panel (ALT/AST, ALP, bilirubin), albumin, and INR. Shows inflammation, bile blockage, and the liver’s protein-making ability; used in Child–Pugh or MELD scores. PMC

10. Alpha-fetoprotein (AFP). A blood marker sometimes high in HCC; helpful but not perfect. PMC

11. Des-gamma-carboxy prothrombin (DCP or PIVKA-II). Another marker that can outperform AFP in some settings; combining AFP with DCP improves detection. MDPI+1

12. AFP-L3%. A cancer-specific AFP fraction; high specificity but lower sensitivity; sometimes combined with AFP and DCP. MDPI

13. Viral hepatitis tests (HBsAg, anti-HCV; HBV DNA/HCV RNA). Identify the cause of liver disease and future risk. World Health Organization

14. Liver biopsy with immunohistochemistry (when imaging is not definitive). Core biopsy confirms HCC and may show typical markers such as glypican-3, heat-shock protein 70, and glutamine synthetase. (Biopsy is not needed if imaging criteria are conclusive.) PMC

D) Electrodiagnostic / physiologic stiffness tests

15. Transient elastography (FibroScan). A handheld probe measures liver stiffness (scarring) non-invasively; high stiffness means higher HCC risk and worse reserve. EASL-The Home of Hepatology.

16. MR or shear-wave elastography. Uses MRI or ultrasound software to map liver stiffness; helps risk-stratify MASLD or viral hepatitis. PMC

E) Imaging tests (the core of diagnosis)

17. Ultrasound (US) for surveillance. Every 6 months in at-risk adults (often with AFP). If US shows a nodule ≥1 cm, move to CT or MRI. PMC

18. Multiphasic contrast-enhanced CT. HCC often shows arterial phase hyperenhancement and then “washout” later; with these features in an at-risk liver, CT can make the diagnosis without biopsy. PMC

19. Multiphasic MRI (with extracellular or gadoxetate contrast). Often more sensitive than CT; looks for the same “arterial up, portal/delayed down” pattern and a capsule. PMC

20. LI-RADS reporting system (applies to CT/MRI and CEUS). Standard words and categories (LR-1 to LR-5) tell how likely a lesion is HCC; LR-5 = definite HCC in the right setting. Contrast-enhanced ultrasound (CEUS) can also support diagnosis. AASLDRadiopaediaRadiology Assistant

Modern guidelines from AASLD and EASL accept a non-invasive diagnosis of HCC when a nodule ≥1 cm in a high-risk liver shows arterial phase hyperenhancement plus washout and/or capsule on CT or MRI, reported using LI-RADS. Biopsy is reserved for unclear cases. PMCJournal of Hepatology

Non-pharmacological treatments

1) Individualized aerobic walking program
Description: A gentle, scheduled walking plan (for example, 15–30 minutes most days) is scaled to fatigue and shortness of breath. Pace is “able to talk, not sing.” Start on flat surfaces, add small hills only if safe. Include a brief warm-up and cool-down.
Purpose: Improve stamina, reduce cancer-related fatigue, and support heart–lung health before and during treatment.
Mechanism: Aerobic exercise increases oxygen delivery, mitochondrial efficiency, and skeletal muscle endurance. It counters de-conditioning and sarcopenia common in cirrhosis/HCC.
Benefits: Better energy, improved mood and sleep, lower insulin resistance, and safer tolerance of therapies. It may reduce risk of falls and hospital de-conditioning.

2) Low-load resistance training with bands
Description: Two to three sessions per week using light elastic bands for large muscle groups (legs, hips, back, chest, shoulders, arms). Perform 1–2 sets of 8–12 slow repetitions, resting as needed.
Purpose: Preserve or rebuild muscle mass and strength in the presence of cirrhosis-related muscle loss.
Mechanism: Progressive loading stimulates muscle protein synthesis and neuromuscular recruitment without stressing the liver.
Benefits: Improved mobility, easier daily activities, better balance, and potential improvement in treatment tolerance.

3) Sit-to-stand practice from a chair
Description: A simple, safe home exercise: sit, cross arms, stand up slowly, then sit down; repeat 5–10 times, 1–2 sets, once or twice daily.
Purpose: Target lower-body strength and functional independence.
Mechanism: Quadriceps and gluteal strengthening improves transfer ability and gait stability.
Benefits: Fewer falls, better confidence, and easier self-care.

4) Step-ups on a low platform
Description: Step up and down on a low step or stair, holding a rail. Begin with short sets, increase as tolerated.
Purpose: Build leg power and cardiovascular conditioning safely.
Mechanism: Repeated concentric/eccentric contractions improve strength and balance control.
Benefits: More walking confidence and reduced fatigue in daily life.

5) Gentle flexibility routine
Description: Ten minutes of slow stretches for hamstrings, calves, hip flexors, chest, and shoulders after warm-up. Hold 15–30 seconds without bouncing.
Purpose: Maintain joint range and reduce stiffness from inactivity or treatment-related aches.
Mechanism: Stretching improves muscle–tendon length and reduces guarding.
Benefits: Easier movement, better posture, and reduced musculoskeletal pain.

6) Diaphragmatic breathing
Description: Slow nasal breaths expanding the abdomen, exhale longer than inhale (for example, 4-in/6-out) for 5–10 minutes, once or twice daily.
Purpose: Calm the nervous system and reduce breathlessness and anxiety.
Mechanism: Activates the parasympathetic system and improves diaphragmatic excursion.
Benefits: Lower stress, steadier heart rate, and better tolerance of exercise.

7) Inspiratory muscle training (IMT)
Description: Breathing through a handheld threshold device set to low–moderate resistance, 5–10 minutes daily.
Purpose: Support respiratory strength in fatigued patients and those with ascites-related breathing restriction.
Mechanism: Adds targeted load to inspiratory muscles, improving strength and endurance.
Benefits: Less dyspnea with activity, better exercise adherence.

8) Balance training (tandem stance and single-leg support with aid)
Description: Practice standing heel-to-toe or on one leg near a counter, 20–30 seconds at a time.
Purpose: Reduce falls in patients with weakness or neuropathy.
Mechanism: Repeated practice enhances proprioception and ankle–hip balance strategies.
Benefits: Safer mobility and confidence walking outdoors.

9) Pacing and energy-conservation coaching
Description: Plan the day with activity–rest cycles; do demanding tasks when energy is best; sit for tasks if possible.
Purpose: Control fatigue so important activities still happen.
Mechanism: Distributes limited energy across the day and prevents post-exertional crashes.
Benefits: Greater control of symptoms and improved quality of life.

10) Postural training for ascites and back discomfort
Description: Teach neutral spine, lumbar support when sitting, and frequent position changes.
Purpose: Ease back strain and improve breathing mechanics.
Mechanism: Better alignment reduces paraspinal overuse and improves diaphragm motion.
Benefits: Less pain and better tolerance of sitting treatments.

11) Gentle yoga (restorative forms)
Description: Simple floor or chair poses with slow breathing, avoiding inversions or high intra-abdominal pressure.
Purpose: Reduce stress, improve flexibility, and aid sleep.
Mechanism: Combines mindfulness with low-intensity stretch and vagal activation.
Benefits: Lower anxiety, improved mood, and body awareness.

12) Tai chi or qigong
Description: Slow, flowing movements performed 10–20 minutes daily.
Purpose: Improve balance, coordination, and mental calm.
Mechanism: Integrates proprioception, controlled weight shift, and attention focus.
Benefits: Reduced falls risk and better perceived well-being.

13) Manual therapy for pain relief (gentle, non-deep)
Description: Light soft-tissue work and joint mobilization by trained therapists; avoid deep or high-pressure techniques over the liver.
Purpose: Decrease muscle guarding and pain.
Mechanism: Modulates pain through mechanoreceptor input and reduces myofascial tension.
Benefits: Short-term pain relief and easier movement.

14) Lymphedema and edema management education
Description: Teach leg elevation, gentle ankle pumps, and proper compression if prescribed.
Purpose: Reduce lower-extremity edema from hypoalbuminemia or venous stasis.
Mechanism: Muscle pump activation plus external compression promotes fluid return.
Benefits: Less heaviness and better walking comfort.

15) Prehabilitation before surgery or ablation
Description: A 2–6-week bundle: aerobic, resistance, nutrition, and breathing practice before scheduled procedures.
Purpose: Enhance readiness and reduce complications.
Mechanism: Improves cardiorespiratory reserve and protein stores.
Benefits: Faster recovery, shorter hospital stay, better outcomes.

Mind-Body, Educational, and Supportive Therapies

16) Mindfulness-based stress reduction (MBSR)
Description: Guided meditation and body scanning 10–20 minutes daily, often via apps.
Purpose: Reduce distress, fear, and insomnia.
Mechanism: Shifts attention, lowers sympathetic arousal, and changes stress appraisal.
Benefits: Better mood, sleep quality, and treatment adherence.

17) Cognitive behavioral therapy for insomnia (CBT-I)
Description: Brief, structured sessions to reset sleep timing, reduce clock-watching, and challenge unhelpful beliefs about sleep.
Purpose: Treat common sleep disruption in HCC.
Mechanism: Alters arousal and sleep association patterns.
Benefits: More restorative sleep and daytime energy.

18) Structured nutrition counseling (liver-friendly)
Description: Dietitian-led plan of adequate protein, small frequent meals, sodium awareness, and safe supplements.
Purpose: Preserve muscle and support liver function.
Mechanism: Optimizes macronutrients, micronutrients, and meal timing to reduce catabolism.
Benefits: Less sarcopenia and better strength.

19) Alcohol-cessation and harm-reduction program
Description: Counseling, peer support, and, if needed, medications from clinicians to stop alcohol.
Purpose: Remove a key driver of liver injury.
Mechanism: Eliminates ongoing hepatotoxic exposure.
Benefits: Slower disease progression and improved transplant candidacy.

20) Hepatitis B/C treatment navigation
Description: Link to antivirals (HBV suppression or HCV cure) and adherence support.
Purpose: Control viral injury to the liver.
Mechanism: Antivirals reduce inflammation and improve liver reserve.
Benefits: Better eligibility for therapies and improved survival.

21) Safe-movement education for ascites and hernia risk
Description: Teach log-rolling to get out of bed, avoid breath-holding during exertion, and lift with exhalation.
Purpose: Lower hernia and pain risk.
Mechanism: Limits spikes of intra-abdominal pressure.
Benefits: Fewer strain injuries.

22) Symptom self-monitoring plan
Description: Keep a diary of pain, swelling, confusion, weight, and temperature.
Purpose: Detect complications early (bleeding, infection, hepatic encephalopathy).
Mechanism: Timely reporting prompts faster care.
Benefits: Avoids severe episodes and admissions.

23) Social work and financial counseling
Description: Help with transport, medication costs, and caregiver support.
Purpose: Reduce practical barriers to treatment.
Mechanism: Connects patients to community and insurance resources.
Benefits: Less stress and better continuity of care.

24) Palliative care co-management
Description: Symptom control (pain, nausea, itching), advance-care planning, and support alongside cancer therapy.
Purpose: Improve quality of life at any stage.
Mechanism: Expert symptom assessment and multimodal relief.
Benefits: Better comfort and often better treatment completion.

25) Smoking-cessation support
Description: Counseling, nicotine replacement, or medicines as appropriate.
Purpose: Improve healing, reduce other cancers and heart risk.
Mechanism: Removes tobacco toxins and improves oxygen delivery.
Benefits: Better overall outcomes and survival.

---

Drug treatments

1) Atezolizumab + Bevacizumab (first-line standard)
Class & purpose: Atezolizumab is a PD-L1 immune checkpoint inhibitor; bevacizumab is an anti-VEGF antibody. Together they help the immune system see the tumor and block blood-vessel growth. Used as first-line therapy for unresectable HCC in eligible patients after variceal screening.
Dose & time: Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV every 3 weeks until progression or toxicity.
Mechanism: PD-L1 blockade activates T-cells; VEGF blockade normalizes tumor vessels and reduces immunosuppression in the tumor microenvironment.
Key side effects: Immune-related reactions (rash, thyroiditis, hepatitis, colitis), and bevacizumab risks (bleeding, hypertension, proteinuria).
Evidence: IMbrave150 showed superior overall survival and progression-free survival vs sorafenib; multiple guidelines list it as preferred first-line. New England Journal of MedicineJournal of HepatologyPMCNCCN

2) Durvalumab + Tremelimumab (STRIDE regimen; first-line option)
Class & purpose: Durvalumab (PD-L1 inhibitor) plus a single priming dose of tremelimumab (CTLA-4 inhibitor) boosts antitumor immunity. Chosen if bleeding risk makes bevacizumab unsuitable or by clinician preference.
Dose & time: One priming dose tremelimumab 300 mg IV + durvalumab 1500 mg IV at cycle 1, then durvalumab 1500 mg IV every 4 weeks until progression/toxicity.
Mechanism: CTLA-4 priming expands T-cell clones; PD-L1 blockade sustains activity.
Key side effects: Immune hepatitis, colitis, endocrinopathies, rash; monitor liver tests closely in cirrhosis.
Evidence: HIMALAYA showed overall-survival benefit vs sorafenib and durable responses; guidelines endorse as first-line alternative. PubMedAnnals of OncologyASCOPubs

3) Lenvatinib (first-line TKI when IO is contraindicated)
Class & purpose: Multikinase inhibitor (VEGFR1–3, FGFR1–4, PDGFRα, RET, KIT). Used first-line if immunotherapy or bevacizumab are not appropriate.
Dose & time: ≥60 kg: 12 mg PO daily; <60 kg: 8 mg PO daily, continuous.
Mechanism: Inhibits angiogenesis and tumor signaling pathways.
Key side effects: Hypertension, fatigue, diarrhea, decreased appetite, hand–foot syndrome, liver enzyme rise.
Evidence: Non-inferior to sorafenib for overall survival in REFLECT; still used when IO is unsuitable; listed by major guidelines. PMC

4) Sorafenib (first-line alternative if needed; more often second-line now)
Class & purpose: Multikinase inhibitor (RAF, VEGFR, PDGFR).
Dose & time: 400 mg PO twice daily, continuous (dose-adjust for tolerance).
Mechanism: Blocks tumor cell proliferation and angiogenesis.
Key side effects: Hand–foot skin reaction, diarrhea, fatigue, hypertension.
Evidence: Historic standard; now used when IO/VEGF regimens are not possible. PMC

5) Regorafenib (second-line after sorafenib if tolerated)
Class & purpose: Multikinase inhibitor (VEGFR1–3, TIE2, RAF, KIT).
Dose & time: 160 mg PO daily, 3 weeks on/1 week off.
Mechanism: Further suppresses angiogenesis and oncogenic signaling.
Key side effects: Hand–foot reaction, hypertension, fatigue, diarrhea, liver enzyme elevation.
Evidence: Improves survival vs placebo in sorafenib-experienced patients (RESORCE); included in guidelines as later-line option. PMC

6) Cabozantinib (second/third-line)
Class & purpose: Multikinase inhibitor (MET, AXL, VEGFR).
Dose & time: 60 mg PO daily, continuous (titrate for toxicity).
Mechanism: Targets pathways linked to resistance and metastasis.
Key side effects: Diarrhea, fatigue, hand–foot syndrome, hypertension.
Evidence: CELESTIAL trial improved overall survival in previously treated HCC; listed in guidelines. PMC

7) Ramucirumab (AFP ≥400 ng/mL; later-line)
Class & purpose: Monoclonal antibody against VEGFR-2, specifically for patients with AFP ≥400 ng/mL after prior therapy.
Dose & time: 8 mg/kg IV every 2 weeks until progression/toxicity.
Mechanism: Blocks VEGF signaling at the receptor, reducing angiogenesis.
Key side effects: Hypertension, bleeding, proteinuria, GI perforation risk (rare).
Evidence: REACH-2 established benefit in the AFP-high subgroup; dosing per label and references. PMCMedscape ReferenceEuropean Medicines Agency (EMA)

8) Pembrolizumab (later-line immunotherapy)
Class & purpose: PD-1 inhibitor for selected previously treated patients when other options are unsuitable.
Dose & time: 200 mg IV every 3 weeks or 400 mg every 6 weeks.
Mechanism: Restores T-cell antitumor activity.
Key side effects: Immune-mediated hepatitis, colitis, pneumonitis, endocrinopathies.
Evidence: Recognized in guideline compendia as an option for pretreated patients where appropriate. Medscape

9) Nivolumab + Ipilimumab (later-line combo)
Class & purpose: PD-1 plus CTLA-4 inhibitors for patients previously treated with sorafenib or other therapy.
Dose & time: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg IV every 3 weeks for 4 doses, then nivolumab maintenance (typical label regimen).
Mechanism: Dual checkpoint blockade expands and sustains cytotoxic T-cell responses.
Key side effects: Higher rate of immune-related toxicities; careful monitoring needed.
Evidence: CheckMate-040 supported approval; long-term updates show durable responses. PubMedJAMA Network

10) Durvalumab monotherapy (when combinations unsuitable)
Class & purpose: PD-L1 inhibitor used if combination therapy is contraindicated.
Dose & time: 1500 mg IV every 4 weeks.
Mechanism: Blocks PD-L1 to maintain T-cell activity.
Key side effects: Immune-related events (hepatitis, thyroid disorders, rash).
Evidence: In HIMALAYA, durvalumab was non-inferior to sorafenib, offering an IO option when bevacizumab or tremelimumab cannot be used. PubMed

11) TACE-sensitizing systemic support (contextual)
Class & purpose: While transarterial chemoembolization (TACE) is a procedure, clinicians sometimes pair it with systemic therapy in trials or outside trials to improve control.
Dose & time: Varies by protocol; decision is individualized.
Mechanism: Combining local ischemia with systemic pathway blockade may limit recurrence between TACE sessions.
Key side effects: Depends on the systemic drug chosen.
Evidence: Strategies are evolving and guideline-concordant use is center-specific. PMC

12) Supportive corticosteroid use
Class & purpose: Not to treat HCC directly, but to manage severe immune-related adverse events from checkpoint inhibitors.
Dose & time: Prednisone equivalent often 0.5–1 mg/kg/day, tapered as per toxicity grade.
Mechanism: Dampens immune over-activation to protect organs.
Key side effects: Hyperglycemia, infection risk, mood changes, muscle loss.
Evidence: Incorporated into immunotherapy toxicity guidelines.

13) Antiviral therapy for HBV
Class & purpose: Nucleos(t)ide analogues (e.g., entecavir, tenofovir) to suppress HBV.
Dose & time: Once daily; long-term.
Mechanism: Reduces viral replication and hepatic inflammation.
Key side effects: Renal/bone monitoring with some agents.
Evidence: Standard of care to protect liver reserve during cancer therapy. PMC

14) Direct-acting antivirals (DAAs) for HCV
Class & purpose: Oral combinations that cure HCV to stop ongoing liver injury.
Dose & time: Typically 8–12 weeks depending on regimen.
Mechanism: Blocks steps in HCV replication.
Key side effects: Usually mild; important drug–drug checks with TKIs.
Evidence: Strongly recommended in guidelines to improve liver health even when cancer is present. PMC

15) Thromboprophylaxis or anticoagulation (select cases)
Class & purpose: Only in specific situations (e.g., portal vein thrombosis without high bleeding risk) under specialist care.
Dose & time: Individualized.
Mechanism: Prevents clot extension and maintains portal flow in selected scenarios.
Key side effects: Bleeding.
Evidence: Case-by-case; decisions must weigh bleeding risk, varices, and procedures.

Important note: Drug choices, doses, and sequences must be individualized by an oncology/hepatology team using current guidelines (AASLD, EASL, ASCO, NCCN). Atezolizumab–bevacizumab and durvalumab–tremelimumab are widely recommended first-line options as of 2024–2025. PMCNCCNASCOPubsEASL-The Home of Hepatology.

---

Dietary molecular supplements

1) Adequate protein with branched-chain amino acids (BCAAs)
Dose: Dietitian-guided; often 1.0–1.5 g/kg/day total protein; BCAA powders per label if prescribed.
Function & mechanism: Counters sarcopenia and supports immune and wound healing; BCAAs are preferentially used by muscle and may aid ammonia handling.
Note: Monitor in hepatic encephalopathy and kidney disease.

2) Vitamin D (if deficient)
Dose: Typical repletion 1000–2000 IU/day or per lab results.
Function & mechanism: Bone and muscle health; immunomodulatory actions; deficiency is common in liver disease.
Note: Avoid mega-doses; recheck levels.

3) Omega-3 fatty acids (EPA/DHA)
Dose: ~1–2 g/day combined EPA+DHA from food or capsules if approved.
Function & mechanism: Anti-inflammatory lipid mediators; may help weight and appetite, and support cardiovascular health.
Note: Watch for bleeding risk with bevacizumab or anticoagulants.

4) Zinc (if low)
Dose: Often 25–50 mg elemental zinc/day short term, with copper monitoring.
Function & mechanism: Enzyme cofactor; deficiency can worsen taste changes, appetite, and cognition in liver disease.

5) Selenium (if low)
Dose: 50–100 mcg/day with dietitian oversight.
Function & mechanism: Antioxidant selenoproteins may help oxidative stress balance.
Note: Excess is toxic.

6) Probiotics (for gut-liver axis support)
Dose: Product-specific; often 10^9–10^10 CFU/day strains used in cirrhosis studies.
Function & mechanism: May reduce gut permeability and endotoxin burden, indirectly supporting liver inflammation control.
Note: Avoid in severe immunosuppression without approval.

7) Thiamine (vitamin B1) when nutrition risk or alcohol history
Dose: Typical 50–100 mg/day orally if risk identified.
Function & mechanism: Supports carbohydrate metabolism and nervous system; prevents deficiency syndromes.

8) Multivitamin without iron (unless iron-deficient)
Dose: Once daily.
Function & mechanism: Covers mild deficits from poor intake; avoid excess fat-soluble vitamins; iron only if deficiency confirmed.

9) Oral nutrition supplements (energy-dense shakes)
Dose: 1–2 servings/day as advised.
Function & mechanism: Adds calories/protein when appetite is low; supports weight maintenance.

10) Cautious use of silymarin (milk thistle) only under clinician advice
Dose: If approved, standardized extracts per label.
Function & mechanism: Antioxidant/hepatocellular membrane effects have been studied, but evidence for HCC outcomes is limited.
Note: Many “liver detox” herbs are unsafe; avoid kava, high-dose green-tea extract, comfrey, and any unlabeled products.

Always discuss supplements with your oncologist or hepatologist. Some herbs and high-dose antioxidants can interact with immunotherapy, TKIs, or increase bleeding.

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved stem-cell drugs that cure HCC. The items below are immune-modulating or regenerative-support strategies that clinicians may use in specific contexts; they do not replace anti-cancer therapy.

1) Vaccination (HBV)
Dose: Per national schedule for non-immune patients.
Function & mechanism: Induces protective antibodies; prevents further HBV-related liver injury during and after HCC treatment.

2) Antiviral therapy (HBV/HCV) as liver-protective measure
Dose: As above (entecavir/tenofovir; DAA combinations).
Function & mechanism: Reduces inflammatory drive and may improve immune surveillance.

3) Nutritional immunotherapy (adequate protein + vitamin D)
Dose: As above.
Function & mechanism: Correcting protein–energy malnutrition and vitamin D deficiency supports innate and adaptive immune function.

4) Granulocyte colony-stimulating factor (G-CSF) for treatment-induced neutropenia
Dose: Intermittent injections per blood counts.
Function & mechanism: Boosts neutrophil production to reduce infection risk during systemic therapy.

5) Hepatic-directed growth factor support is investigational (e.g., cell-based therapies)
Dose: Only in clinical trials.
Function & mechanism: Aims to regenerate liver tissue; not standard for HCC.
Note: Ask your team about trial eligibility.

6) Exercise immunology (regular moderate activity)
Dose: 150 minutes/week moderate activity if safe.
Function & mechanism: Exercise improves NK-cell surveillance, lowers systemic inflammation, and supports vaccine responses.

---

Surgeries

1) Anatomical liver resection (segmentectomy/lobectomy)
Procedure: Surgical removal of the tumor with the liver segment(s) that contain it, often using intraoperative ultrasound.
Why it’s done: Curative option for a single tumor with good liver reserve, no major vessel invasion, and no portal hypertension.

2) Non-anatomical (wedge) resection
Procedure: Removes the tumor with a margin while sparing liver tissue when anatomy allows.
Why it’s done: Useful when location permits a safe margin and liver function is borderline for bigger resections.

3) Liver transplantation
Procedure: Removes the entire diseased liver and replaces it with a donor liver (deceased or living donor).
Why it’s done: Curative for patients meeting criteria (such as Milan criteria) when cirrhosis is advanced; treats both tumor and liver failure.

4) Laparoscopic radiofrequency or microwave ablation (surgical setting)
Procedure: Under laparoscopy, probes are inserted into the tumor to heat and destroy it.
Why it’s done: Curative for small tumors when resection is not feasible or as a bridge to transplant.

5) Irreversible electroporation (selected centers)
Procedure: High-voltage pulses create nanopores in tumor cell membranes to induce cell death without heat.
Why it’s done: Considered near critical vessels or bile ducts where thermal ablation risks injury; availability varies.

(Interventional oncology procedures such as TACE and radioembolization are also widely used but are not “surgeries.” They are catheter-based therapies performed by interventional radiologists and often integrated with systemic therapy.)

---

Preventions

1. Get vaccinated for hepatitis B if not immune.

2. Treat hepatitis C with direct-acting antivirals to cure infection.

3. Avoid aflatoxin (store grains/nuts dry and safe; avoid moldy foods).

4. Limit or stop alcohol to protect the liver.

5. Maintain healthy weight and treat metabolic syndrome to reduce NASH.

6. Control diabetes and blood pressure to lower fatty-liver injury.

7. Avoid unnecessary steroids and anabolic agents that strain the liver.

8. Use clean needles and safe medical practices to prevent viral spread.

9. Do regular ultrasound surveillance (with or without AFP) if you are at high risk (cirrhosis or chronic HBV).

10. Do not use unverified herbal remedies that may be hepatotoxic.

---

When to see doctors

• Immediately (emergency): Vomiting blood or black stools, sudden severe abdominal pain, confusion or extreme sleepiness (possible hepatic encephalopathy), fever with chills, yellow eyes with severe itching, rapid belly swelling, or fainting.

• Prompt appointment: New or worsening right-upper-quadrant pain, unexplained weight loss, persistent fever, worsening fatigue, marked leg swelling, or new jaundice.

• Routine/ongoing: People with cirrhosis or chronic HBV/HCV should have regular liver ultrasounds and labs every 6 months, or as advised.

---

What to eat and what to avoid

• Eat:

1. Small, frequent meals with adequate protein (fish, eggs, beans, lean meats) to prevent muscle loss.

2. Complex carbohydrates like rice, oats, and whole grains for steady energy.

3. Healthy fats from olive oil, nuts, and seeds.

4. Fruits and vegetables for fiber and micronutrients (wash well).

5. Dairy or fortified alternatives for calcium and vitamin D if tolerated.

• Avoid or limit:

6. Alcohol (stop completely).

7. Very salty foods (canned soups, pickles, fast food) if you have ascites or swelling.

8. Uncooked shellfish (infection risk).

9. Herbal “detox” products and bodybuilding supplements with unknown ingredients.

10. Large single heavy meals late at night; choose lighter, frequent meals instead.

---

FAQs

1) Is HCC always linked to cirrhosis?
Most cases occur on top of cirrhosis, but HCC can also arise without cirrhosis, especially with chronic hepatitis B or aflatoxin exposure.

2) How is HCC diagnosed?
Often by characteristic patterns on contrast CT or MRI plus blood tests (AFP). Sometimes a biopsy is needed when imaging is unclear. PMC

3) What staging system is used?
Commonly the Barcelona Clinic Liver Cancer (BCLC) system, which includes tumor stage, liver function (Child-Pugh), and performance status to guide therapy. PMC

4) Can early HCC be cured?
Yes. Surgical resection, ablation, or liver transplant can be curative in early stages, depending on tumor size/location and liver reserve. PMC

5) What is first-line systemic therapy today?
Most guidelines favor atezolizumab + bevacizumab or durvalumab + tremelimumab for eligible patients. Lenvatinib or sorafenib are options if these are not suitable. NCCNASCOPubs

6) Why must varices be checked before bevacizumab?
Bevacizumab can increase bleeding risk; screening and treating varices first lowers that risk. PMC

7) What if immunotherapy is not safe for me?
Oral TKIs (lenvatinib or sorafenib) are alternatives. Your team will choose based on liver tests, other illnesses, and bleeding risk. PMC

8) What are common side effects of immunotherapy?
Immune inflammation of organs (skin, thyroid, liver, gut, lungs). Most are manageable if reported early. PMC

9) Will I lose my hair on these treatments?
Hair loss is uncommon with immunotherapy and TKIs, though hair thinning or texture changes can occur. TACE or chemotherapy (if used) may have different effects.

10) Can diet cure HCC?
No. Diet supports strength and tolerance of treatment, but it does not replace cancer therapy.

11) Should I drink coffee?
Some studies link coffee with lower chronic liver disease risk, but it is not a cancer treatment. Ask your clinician if coffee is okay for you.

12) Can I exercise during treatment?
Yes, with guidance. Start low and go slow. Exercise can reduce fatigue and maintain muscle.

13) What about TACE and radioembolization?
These catheter-based treatments deliver therapy directly to the tumor’s blood supply and are commonly used for intermediate stages or when surgery is not possible. PMC

14) What is AFP and why does it matter?
Alpha-fetoprotein is a blood marker sometimes elevated in HCC. Very high AFP (≥400 ng/mL) also guides use of ramucirumab in later lines. PMC

15) How often will I be scanned?
Typically every 2–3 months during systemic treatment, but timing varies by regimen and response.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 09, 2025.